Gemcitabine in advanced breast cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Advanced or metastatic breast cancer presents significant treatment challenges.
• Single-agent chemotherapy is a common approach for palliation and improving quality of life.

Purpose of the Study:

• To review the clinical experience with single-agent gemcitabine in advanced or metastatic breast cancer.
• To evaluate the efficacy and toxicity profile of gemcitabine in this patient population.

Main Methods:

• Gemcitabine administered as a 30-minute intravenous infusion weekly for 3 weeks, followed by 1 week of rest.
• Two European studies and one US study were reviewed, with varying patient populations and gemcitabine doses.
• Response rates, time to response, survival, and toxicities (hematological and non-hematological) were assessed.

Main Results:

• In the first European study (800 mg/m2/week), an overall response rate of 25.0% was observed in 40 evaluable patients, with a median survival of 11.5 months.
• Toxicities were generally mild, with notable but manageable rates of leukopenia, neutropenia, and nausea/vomiting.
• A smaller US study with a lower delivered dose showed no responders, while an ongoing European trial with a higher dose (1000 mg/m2) has shown partial responses.

Conclusions:

• Single-agent gemcitabine demonstrates modest activity and a favorable toxicity profile in advanced breast cancer.
• Its profile makes gemcitabine a potential candidate for combination therapy trials in this setting.
• Further investigation is needed to optimize its use in advanced breast cancer treatment strategies.